Schwab Charles Investment Management Inc. boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,127,294 shares of the medical equipment provider’s stock after acquiring an additional 74,771 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Hologic were worth $42,116,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Fiduciary Trust Co. bought a new stake in Hologic during the fourth quarter worth approximately $208,000. Endurant Capital Management LP increased its stake in Hologic by 115.9% during the fourth quarter. Endurant Capital Management LP now owns 222,844 shares of the medical equipment provider’s stock worth $9,527,000 after acquiring an additional 119,641 shares during the last quarter. Ascend Capital LLC bought a new position in shares of Hologic during the fourth quarter valued at approximately $11,016,000. Flinton Capital Management LLC grew its stake in shares of Hologic by 9.2% during the fourth quarter. Flinton Capital Management LLC now owns 18,904 shares of the medical equipment provider’s stock valued at $808,000 after buying an additional 1,598 shares during the last quarter. Finally, Amalgamated Bank grew its stake in shares of Hologic by 9.5% during the fourth quarter. Amalgamated Bank now owns 36,020 shares of the medical equipment provider’s stock valued at $1,540,000 after buying an additional 3,118 shares during the last quarter. 99.80% of the stock is currently owned by institutional investors.
Get Hologic alerts:
Shares of Hologic opened at $38.89 on Wednesday, according to Marketbeat.com. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $10.67 billion, a P/E ratio of 19.16, a PEG ratio of 1.84 and a beta of 0.87. Hologic, Inc. has a 52-week low of $35.10 and a 52-week high of $46.80.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.53. The firm had revenue of $789.30 million during the quarter, compared to analyst estimates of $781.23 million. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. Hologic’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.50 earnings per share. analysts anticipate that Hologic, Inc. will post 2.24 EPS for the current year.
A number of research analysts have recently commented on HOLX shares. Goldman Sachs cut Hologic from a “conviction-buy” rating to a “buy” rating and set a $43.00 target price on the stock. in a research note on Monday, March 26th. Zacks Investment Research cut Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $43.00 target price (down previously from $50.00) on shares of Hologic in a research note on Tuesday, May 1st. BidaskClub raised Hologic from a “strong sell” rating to a “sell” rating in a research note on Wednesday, April 18th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and set a $44.00 target price on shares of Hologic in a research note on Friday, February 9th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the stock. Hologic currently has an average rating of “Hold” and a consensus target price of $44.87.
In related news, SVP Allison P. Bebo sold 7,000 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $38.75, for a total value of $271,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Karleen Marie Oberton sold 12,196 shares of the business’s stock in a transaction that occurred on Wednesday, May 2nd. The shares were sold at an average price of $40.00, for a total value of $487,840.00. Following the completion of the sale, the vice president now owns 13,825 shares of the company’s stock, valued at approximately $553,000. The disclosure for this sale can be found here. 0.88% of the stock is currently owned by insiders.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).